Physician profile
Daniel Pevril
NPI 1649811415
$3,968.30
in general payments reported to CMS, 2019-2025
32 companies · $1,249 in 2025
The $1,249 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $860 · 2022: $722 · 2023: $734 · 2024: $403 · 2025: $1,249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,187 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,186.90 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $730.58 | 2022-2025 | Interstim, Altaviva, Nuro |
| Astellas Pharma US INC | $667.18 | 2021-2024 | Xtandi, Veozah, Myrbetriq |
| Janssen Biotech, INC. | $467.34 | 2021-2025 | Erleada, Rybrevant, Carvykti |
| Myriad Genetic Laboratories, INC. | $241.61 | 2021-2024 | Prolaris |
| Olympus America INC. | $206.01 | 2025 | Itind System |
| Tolmar, INC. | $166.37 | 2024-2025 | Jatenzo, Eligard |
| Axonics, INC. | $155.52 | 2021-2022 | |
| Boston Scientific Corporation | $133.01 | 2021-2025 | Ams 700 Cxr Rte Kit, Spaceoar System, Axonics |
| Pfizer INC. | $125.68 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.37 | 2023-2025 | |
| Urogen Pharma, INC. | $101.43 | 2021-2025 | Jelmyto |
| Blue Earth Diagnostics | $93.04 | 2021-2022 | |
| Abbvie INC. | $84.05 | 2023-2025 | |
| Accord Healthcare, INC. | $77.95 | 2023-2025 | |
| Baudax Bio INC. | $74.04 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar Pharmaceuticals, INC. | $65.99 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $54.55 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $50.11 | 2023-2025 | Gemtesa, Orgovyx |
| Novo Nordisk INC | $41.52 | 2021 | |
| Urovant Sciences INC | $41.29 | 2022 | |
| Convatec INC. | $33.38 | 2023 | |
| Endo Pharmaceuticals INC. | $30.98 | 2023 | Xiaflex, Aveed |
| Caris Mpi, INC. | $29.59 | 2025 | Mi Cancer Seek |
| Myovant Sciences INC. | $27.06 | 2021-2022 | |
| 180 Medical, INC. | $23.08 | 2025 | Gentlecath Glide |
| Coloplast Corp | $22.33 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $20.35 | 2021 | |
| Teleflex LLC | $18.00 | 2021 | |
| Radius Health, INC. | $17.77 | 2021 | |
| Procept Biorobotics Corporation | $15.48 | 2024 | Aquabeam System |
| Amgen INC. | $15.04 | 2021 | |
| Allergan, INC. | $13.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Pevril listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.